Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapy

被引:14
作者
Jones, ME
Karlowsky, JA
Draghi, DC
Thornsberry, C
Sahm, DF
Nathwani, D
机构
[1] Focus Technol Inc, Herndon, VA USA
[2] Tayside Univ Hosp, Infect & Immunodeficiency Unit, Dundee, Scotland
关键词
bone infections; osteomyelitis; antibiotic resistance; surveillance;
D O I
10.1016/j.ijantimicag.2003.08.007
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Bone infections, which can be acute or chronic, often require aggressive antibiotic therapy, whether treated at home or in the community. Surveillance programmes are essential tools in the monitoring of antimicrobial resistance and can act as a resource to maintain effective prescribing. The Surveillance Network(R) (TSN(R)), which collects organism and patient-specific data from a network of laboratories across the United States, was used to analyse susceptibility of common bacterial species isolated from bone infections during 2000-2002. Narrow-spectrum antimicrobials such as vancomycin, quinupristin-dalfopristin and linezolid demonstrated good activity against Staphylococcus aureus and streptococci, and were active against 100% of isolates. However, Gram-negative species were also commonly isolated from these sites of infection. Later-generation cephalosporins, represented by ceftriaxone, cefotaxime and cefepime, exhibited a broad spectrum of activity including Enterobacteriaceae, streptococci and methicillin-susceptible S. aureus, but they were not active against methicillin-resistant S. aureus (MRSA) and showed variable activity against Pseudomonas aeruginosa. Using ceftazidime as a marker for extended spectrum p-lactamase (ESBL) expression, less than 3% of Escherichia coli or Klebsiella pneumoniae expressed this phenotype. Based on current in vitro activity, the third-generation cephalosporins provide broad-spectrum coverage useful for the empirical therapy of suspected bone infections, especially for patients treated in the community or hospitalised with community-acquired infections. (C) 2003 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:240 / 246
页数:7
相关论文
共 20 条
[1]  
Carek PJ, 2001, AM FAM PHYSICIAN, V63, P2413
[2]   NEW THREATS TO THE CONTROL OF METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].
CASEWELL, MW .
JOURNAL OF HOSPITAL INFECTION, 1995, 30 :465-471
[3]   Osteomyelitis in elderly patients [J].
Cunha, BA .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (03) :287-293
[4]   Ceftriaxone therapy for staphylococcal osteomyelitis: A review [J].
Guglielmo, BJ ;
Luber, AD ;
Paletta, D ;
Jacobs, RA .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) :205-207
[5]   Screening and confirmatory testing for extended spectrum β-lactamases (ESBL) in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca clinical isolates [J].
Hadziyannis, E ;
Tuohy, M ;
Thomas, L ;
Procop, GW ;
Washington, JA ;
Hall, GS .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (02) :113-117
[6]   Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000:: results from The Surveillance Network® (TSN®) Database-USA [J].
Karlowsky, JA ;
Jones, ME ;
Mayfield, DC ;
Thornsberry, C ;
Sahm, DF .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (05) :413-426
[7]   Osteomyelitis [J].
Lew, DP ;
Waldvogel, FA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (14) :999-1007
[8]   BETA-LACTAMASES IN LABORATORY AND CLINICAL RESISTANCE [J].
LIVERMORE, DM .
CLINICAL MICROBIOLOGY REVIEWS, 1995, 8 (04) :557-&
[9]   Penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone [J].
Lovering, AM ;
Walsh, TR ;
Bannister, GC ;
MacGowan, AP .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (04) :483-486
[10]   The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin [J].
Moise, PA ;
Forrest, A ;
Birmingham, MC ;
Schentag, JJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (06) :1017-1026